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Abstract
Background: To compare nondestructive in vivo and ex vivo micro-computed tomography (mCT) and ex vivo dual-energy-
X-ray-absorptiometry (DXA) in characterizing mineralized cortical and trabecular bone response to prostate cancer involving
the skeleton in a mouse model.
Methodology/Principal Findings: In vivo mCT was performed before and 10 weeks after implantation of human prostate
cancer cells (MDA-PCa-2b) or vehicle into SCID mouse femora. After resection, femora were imaged by nondestructive ex
vivo specimen mCT at three voxel sizes (31 m,1 6m,8m) and DXA, and then sectioned for histomorphometric analysis of
mineralized bone. Bone mineral density (BMD), trabecular parameters (number, TbN; separation, TbSp; thickness, TbTh) and
mineralized bone volume/total bone volume (BV/TV) were compared and correlated among imaging methods and
histomorphometry. Statistical tests were considered significant if P,0.05. Ten weeks post inoculation, diaphyseal BMD
increased in the femur with tumor compared to the opposite femur by all modalities (p,0.005, n=11). Diaphyseal BMD by
in vivo mCT correlated with ex vivo 31 and 16 mm mCT and histomorphometry BV/TV (r=0.91–0.94, P,0.001, n=11). DXA
BMD correlated less with bone histomorphometry (r=0.73, P,0.001, n=11) and DXA did not distinguish trabeculae from
cortex. By in vivo and ex vivo mCT, trabecular BMD decreased (P,0.05, n=11) as opposed to the cortex. Unlike BMD,
trabecular morphologic parameters were threshold-dependent and when using ‘‘fixed-optimal-thresholds,’’ all except TbTh
demonstrated trabecular loss with tumor and correlated with histomorphometry (r=0.73–0.90, P,0.05, n=11).
Conclusions/Significance: Prostate cancer involving the skeleton can elicit a host bone response that differentially affects
the cortex compared to trabeculae and that can be quantified noninvasively in vivo and nondestructively ex vivo.
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Introduction
Prostate carcinoma is the most frequently diagnosed visceral
cancer and the second most common cause of cancer-related
death among American men [1], [2]. It has a proclivity to
metastasize to bone [3], [4]; and, this is believed to be due not only
to passive hemodynamic factors, but also the bone marrow
microenvironment [5–7]. There is interplay between the tumor
and the host bone, with each affecting the other. Because the
prognosis for patients with prostate cancer deteriorates markedly
once the disease escapes the gland, greater understanding of the
interaction of prostate cancer with bone is needed. However,
progress in such research has been limited by the need for
nondestructive, quantitative imaging methods.
Because of the low levels of bone metastasis with prostate cancer
models [8–15], techniques for direct injection into bone have been
established [16–19]. Using such a mouse model, we have
previously demonstrated that prostate cancer burden involving
bone can be quantified using MR [20]. The ability to
nondestructively image mineralized bone at high resolution under
controlled experimental conditions in animal models [21], [22] is
also needed. For small animals, micro-CT (mCT), which has
spatial resolution in the order of microns, can be utilized. With the
advent of newer generation clinical CT scanners, spatial and
temporal resolution have continuously improved, suggesting
assessment of trabeculae will soon be feasible with clinical
scanners. Thus, knowledge of critical parameters for such
assessment is needed.
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9854Dual-energy X-ray absorptiometry (DXA) is commonly used
clinicallyto measure bone mineraldensity BMD [23], [24]. However,
2D DXA provides relatively low spatial resolution compared to mCT
and does not distinguish trabeculae. Bone histomorphometry can be
used to assess the trabecular structure in animals, but it is invasive,
destructive, as well as labor and time intensive.
mCT provides three-dimensional (3D) representations of bones
and is now available at various resolutions [25]. However, the
affect of thresholding on gross measures such as BMD and
morphologic trabecular parameters is as yet unclear. Most mCT
work has used automated thresholding techniques that normalize
to bone density within the region of interest, but the density may
be altered in pathologic conditions such as osteopenia, and more
so with localized disease such as prostate cancer. We hypothesized
that fixed ‘‘optimal thresholds’’ would be superior to commonly
used ‘‘automated thresholds,’’ which vary by each object
examined, in a quantifying trabecular response to prostate cancer.
With localized disease, we hypothesized that the affect of prostate
tumor on trabecular-mineralized bone may vary from mineralized
cortical bone since cancer generally first involves the marrow.
Such evaluation may be afforded by the three dimensional nature
of mCT. Since mCT can also be performed non-invasively in vivo,
it is desirable because it enables longitudinal studies of the
response of mineralized bone to prostate cancer; however, it
commonly provides less spatial resolution than ex vivo mCT;
therefore, comparison with ex vivo analyses is needed.
We compared the ability of in vivo mCT, ex vivo specimen
mCT, and ex vivo DXA to characterize mineralized cortex and
trabeculae in a mouse model of prostate cancer involving bone.
Materials and Methods
1.1. Cell Culture
MDA-PCa-2b human prostate cancer cells were grown [20] in
BRFF-HPC1 medium (Biological Research Faculty and Facility,
Athena Environmental Services, Baltimore, MD, USA) supple-
mented with 20% fetal bovine serum (Life Technologies, Inc.,
Gaithersburg, MD, USA), 91 U/ml penicillin, 91 mg/ml strepto-
mycin, and 2 mM glutamine. MDA-PCa-2b cells have been
shown to engraft in the marrow cavity of bones, to be hormonally
responsive, and to produce prostate-specific antigen [26–29].
1.2. Animals
Eight-week-old male severe combined immunodeficient (SCID)
mice (n=14) were purchased from Charles River Laboratories
(Wilmington, MA, USA) and housed in specific-pathogen-free
conditions. They were cared for in accordance with guidelines set
forth by the Association for Assessment and Accreditation of
Laboratory Animal Care and the U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals. The
University of Texas M. D. Anderson Cancer Center’s Institutional
Animal Care and Use Committee approved all studies.
1.3. In Vivo Studies
For in vivo imaging procedures, SCID mice were anesthetized by
inhalation of 2% isoflurane. The femora (n=14 mice) were first
scanned using in vivo mCT as described below. After baseline
imaging, 5610
5 MDA-PCa-2b cells [26], [29] in 5 ml of growth
medium were injected into the distal epiphysis of the right femur of
each mouse [26], [29]. The distal epiphysis of the contralateral femur
was injected with 5 ml of vehicle (Phosphate Buffer Solution (PBS)) to
serveasacontrol.Threemicediedimmediatelyafter tumor injection.
Ten weeks after tumor inoculation, the femora were again
imaged in vivo by mCT (n=11). The animals were euthanized and
the femora were removed. The disarticulated femora without
muscle were fixed in formalin and stored in 10% ethanol for ex
vivo specimen mCT and ex vivo DXA. The femora were then
processed for bone histomorphometry.
1.4. In Vivo mCT
For in vivo scans, SCID mice were imaged supine using a mCT
scanner at a 91-mm isotropic voxel size (model RS-9, General
Electric Medical, London, Ontario, Canada). The scanner has a
fixed tungsten anode with a focal spot size of 50630 mm. Images
of the femora were acquired at an isotropic voxel size of
91691691 mm using the following scan parameters: 80 kVp,
450 mA, 100 msec per frame, and 3 frames per view.
A calibration standard was positioned in the field-of-scan view
to enable the conversion of Hounsfield units (HU) into BMD
values. MicroView software (version: 2.1.1; General Electric
Medical) was used to view the images and calculate the BMD
(in mg/cm
3) of each femoral diaphysis. For this calculation, a
standard measuring cylinder (2.562.565 mm) was placed so that
its bottom was 1.5 mm above the bone’s growth plate. BMD was
calculated for the right and left femora, and the absolute difference
in BMD values between the right and left femora was determined.
Another cylinder (1.561.560.6 mm) was centered in all three
planes within the metaphysis (excluding cortical bone) with the
bottom at the beginning of the growth plate for the measurement
of BMD and trabecular morphometric parameters. These
parameters (TbN, number of trabeculae/mm; TbSp, trabecular
separation/mm; TbTh, trabecular thickness/mm; and BV/TV,
mineralized bone volume per total bone volume/%) were
measured at fixed thresholds and at automatic thresholds (with
values determined by the software) of mineralized bone. The
BMD, TbTh, TbN, TbSp, and BV/TV obtained by mCT were
correlated with the values obtained by bone histomorphometry.
‘‘Optimal threshold’’ was defined as the threshold that resulted in
maximum correlation between the trabecular parameter by mCT
and that by bone histomorphometry.
1.5. Ex Vivo specimen mCT
Ex vivo specimen mCT of the same femora was performed using
31-mm, 16-mm, and 8-mm voxel sizes on an Explore Locus SP
preclinical specimen scanner (General Electric Medical). This
scanner has a cone-beam volume CT system that uses a tungsten
source X-ray tube operating at 80 kV and 80 mA. The object in
the scanner is rotated in 0.4-degree increments on a holder
between the X-ray source and charge-coupled device-based
detector. Each bone specimen required approximately 4 hours
for data acquisition. After raw images were normalized and
defective detector pixels were corrected, a low-resolution scout
volume was reconstructed using a modification of the method used
by Feldkamp et al. [25] The scout volume was used to select the
coordinates for a distal femur volume of interest, which was
reconstructed into 31-mm, 16-mm, and 8-mm isotropic voxels. The
images were viewed and analyzed for BMD, TbTh, TbN, TbSp,
and BV/TV using the MicroView program as described above.
We also obtained maximum gray-scale fixed-threshold values for
both the diaphysis and metaphysis of each femur. Because of its
limited field of view, the 8-mm acquisition covered only the
metaphysis.
1.6. DXA
Matched left and right femur pairs from the 11 SCID mice were
scanned ex vivo in a sagittal plane using a DXA scanner (Norland
Medical Systems, Inc., New York, NY USA). A rectangular
(2.565 mm) region of interest that encompassed the diaphysis was
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2). Because
the trabeculae were not distinguishable from cortical bone,
trabeculae were not analyzed with DXA.
1.7. Bone Histomorphometry
Representative 5-mm-thick sagittal sections through the entire
width of the femur were obtained at three different levels (right,
mid, and left) for bone histomorphometry measurements. The
three histologic sections per femur were analyzed after Von Kossa
staining for mineralized bone [25]. Cortical thickness was visually
assessed and compared with visual assessments of mCT, DXA, and
histomorphometry data. Using a trabecular analysis system
(Osteometrics, TAS, version 20.8, Atlanta, GA, USA), the images
obtained from the sagittal sections were viewed, and a rectangular
region of interest was placed over each femur diaphysis
(2.565 mm) or metaphysis (1.560.6 mm) in order to measure
TbTh, TbN, TbSp, and BV/TV. Mineralized bone was
calculated in terms of BV/TV, as described above. Care was
taken to match the size and placement of the rectangular region of
interest with the size and placement of the cylindrical region used
in the MicroView program to evaluate the mCT data sets.
1.8. Statistical Analysis
Linear regression was performed to analyze correlations
between values obtained from in vivo and ex vivo mCT, DXA,
and bone histomorphometry studies using Excel software (2003
SP2; Microsoft, Bellevue, WA, USA). Student’s t-test (two-sided)
was used to compare values between the right and left femora.
Pearson’s correlation coefficient was calculated for differences
between imaging techniques, and Fisher’s Z transformation of the
correlation coefficient was employed using SAS software (SAS
Institute, Cary, NC, USA). For all tests, P,0.05 was considered
significant.
Results
2.1. Change in Diaphyseal BMD with Prostate Cancer
Involvement
Qualitatively, in vivo mCT showed no apparent difference in
cortical thickness between the left and right femora before tumor
injection; whereas, diaphyseal cortical thickening and trabecular
alterations were noted using in vivo and ex vivo mCT 10 weeks
after inoculation of the right femur with prostate cancer cells, but
not the control left femur injected with vehicle (Figure 1).
Quantitatively (Figure 2), there was no difference in BMD
between the left and right femoral diaphyses before tumor
injection by in vivo mCT. The mean absolute difference (MAD)
in BMD between right and left femoral diaphyses was
6.964.3 mg/cm
3. Ten weeks after tumor inoculation, the BMD
of the femora with tumors increased (P,0.003), with a MAD of
Figure 1. Representative in vivo and ex vivo mCT images demonstrate cortical thickening induced by prostate cancer involving
bone. Sagittal in vivo longitudinal mCT scans obtained at 91 mm voxel size before and 10 weeks after (A) intrafemoral injection of vehicle control (left
images) or MDA-PCa-2b human prostate cancer cells (right images) show cortical thickening (arrow) in the femora containing tumors. Ex vivo
specimen mCT scans of excised femora at voxel sizes of 31-mm (B), 16-mm (C), and 8-mm (D) also show cortical thickening of the right femur with
tumor. At the 8-mm voxel size, only the distal aspect of the femur was covered by the scans.
doi:10.1371/journal.pone.0009854.g001
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3. Results were concordant between in vivo
mCT and ex vivo specimen mCT with voxel sizes of 31-mm
(P,0.005, n=11, MAD=182.96168.7 mg/cm
3) and 16 mm
(P,0.005, n=11, MAD=167.56163.4 mg/cm
3). The variations
in standard deviations are due to biologic differences in tumor
growth and host response in individual animals, yet significant
differences (P,0.01) were noted. Representative images show that
all methods (in vivo mCT at 91 mm voxel size, ex vivo specimen
mCT at 31, 16, and 8-mm voxel sizes, DXA, and bone
histomorphometry) demonstrated host bone response to the
prostate cancer (Figure 3), including cortical thickening of the
diaphysis (P,0.01, n=11, by 91, 31, and 16-mm voxel size CT,
DXA, and bone histomorphometry, Figure 2 and data not
shown). However, DXA did not distinguish the trabecular change,
whereas, mCT and bone histomorphometry did.
2.2. Correlation of Diaphyseal BMD Values Obtained by In
Vivo and Ex Vivo mCT, Ex Vivo DXA, and Bone
Histomorphometry
There was high correlation of diaphyseal in vivo mCT BMD
and ex vivo mCT BMD and BMD among ex vivo mCT at 31-mm-
and 16-mm-voxel size (Figure 4, Table 1). In comparison, BMD
correlated moderately between DXA and in vivo mCT, or ex vivo
mCT (Figure 4, Table 1).
Diaphyseal BMD by in vivo mCT or ex vivo mCT at 31-mm- or
16-mm-voxel size correlated highly with BV/TV by bone
histomorphometry (Figure 5, Table 1). In comparison, DXA
BMD correlated moderately with the bone histomorphometry
BV/TV (Figure 5, Table 1). In addition, the correlations
between in vivo mCT and ex vivo mCT, at 31-mm or 16-mm, were
higher than those between DXA and ex vivo mCT, at 31-mmo r
16-mm( Table 1).
2.3. Metaphyseal Parameters and Fixed Threshold
Because trabeculae were located primarily in the metaphysis, we
focused on the metaphysis for trabecular assessments. We
compared trabecular BMD and morphometric parameters
obtained by in vivo or ex vivo mCT at different thresholds with
bone histomorphometry. Thresholding did not affect trabecular
BMD obtained using in vivo or ex vivo mCT, but did affect mCT-
derived morphometric parameters such as TbN, BV/TV, TbSp
(Figure 6, Tables 2 and 3), and TbTh (Tables 2 and 3). mCT
performed at each voxel size had individual narrow ranges for best
thresholds for maximum correlation of trabecular parameters
when compared to bone histomorphometry and these narrow
ranges overlapped for TbN, BV/TV, and TbSp. At all voxel sizes
and thresholds, mCT-derived TbTh did not correlate well with
TbTh by bone histomorphometry (r,0.17, P.0.47, n=11), likely
because the small size of trabeculae caused volume-averaging
artifacts.
The automatic threshold or maximum gray-scale threshold
usually did not return the optimal threshold (Table 2). The
automatic threshold ranged from 550 to 975 HU in the left femora
and 350 to 1250 HU in the right femora, and the values varied
between animals and voxel sizes. Similarly, the maximum gray-
scale threshold values ranged from 706 to 855 HU in the left
femora and 744 to 915 HU in the right femora, and these values
also varied between animals and voxel sizes. Correlations between
Figure 2. Bone mineral density (BMD) of the diaphysis was greater in the femora involved by prostate cancer. Diaphyseal BMD was
measured in both femora by in vivo mCT before injection (A) and 10 weeks after injection (B) of vehicle (left femora) or prostate cancer cells (right
femora), and then by ex vivo specimen mCT at 31 mm (C) and 16 mm (D) voxel sizes.
doi:10.1371/journal.pone.0009854.g002
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PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9854Figure 3. Representative in vivo and ex vivo images demonstrate morphologic changes of mineralized cortical and trabecular bone
induced by prostate cancer involving the skeleton. Sagittal in vivo mCT and ex vivo specimen mCT images of femora 10 weeks after injection of
vehicle (left) or prostate cancer cells (right). (A) In vivo mCT (91-mm voxel size); (B) ex vivo specimen mCT at 31-mm, 16-mm, and 8-mm voxel sizes; (C) ex
vivo dual-energy X-ray absorptiometry (DXA); and (D) bone histomorphometry images are presented. L, left femur; R, right femur with tumor; arrow,
cortical thickening.
doi:10.1371/journal.pone.0009854.g003
Figure 4. In vivo mCT and ex vivo specimen mCT measurements of bone mineral density (BMD) correlate with each other and with ex
vivo dual-energy X-ray absorptiometry (DXA) BMD measurements. (A) In vivo mCT at 91-mm vs ex vivo mCT at 31-mm voxel size. (B) In vivo
mCT at 91-mm vs ex vivo mCT at 16-mm voxel size. (C) In vivo mCT at 91-mm vs ex vivo DXA. (D) Ex vivo mCT at 16-mm vs ex vivo DXA.
doi:10.1371/journal.pone.0009854.g004
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9854Figure 5. In vivo mCT, ex vivo specimen mCT, and DXA measurements of diaphyseal bone mineral density (BMD) correlate with
histomorphometry. In vivo mCT (91-mm, A), ex vivo specimen mCT (31-mm, B; 16-mm, C), and DXA (D) measurements of bone mineral density (BMD)
correlate with histomorphometric measurements of mineralized bone volume/total bone volume (BV/TV).
doi:10.1371/journal.pone.0009854.g005
Table 1. Correlations between diaphyseal or metaphyseal BMD determined by bone histomorphometry and in vivo mCT, ex vivo
specimen mCT or ex vivo DXA 10 weeks after tumor inoculation.
Technique BMD At diaphysis BMD At metaphysis
rP r P
91 mm vs DXA 0.83 ,0.001 - -
31 mm vs DXA 0.73 ,0.001 - -
16 mm va DXA 0.75 ,0.001 - -
91 mmv s3 1mm 0.93 ,0.001 0.95 ,0.001
91 mmv s1 6mm 0.94 ,0.001 0.95 ,0.001
91 mmv s8mm - - 0.97 ,0.001
31 mmv s1 6mm 0.98 ,0.001 0.96 ,0.001
31 mmv s8mm - - 0.95 ,0.001
16 mmv s8mm - - 0.97 ,0.001
91 mm vsHistomorphometry 0.92 ,0.001 0.78 ,0.001
31 mm vsHistomorphometry 0.91 ,0.001 0.75 ,0.001
16 mm vsHistomorphometry 0.92 ,0.001 0.77 ,0.001
8 mm vsHistomorphometry - - 0.84 ,0.001
DXA vsHistomorphometry 0.73 ,0.001 - -
*In vivo mCT, 91 mm; Ex vivo mCT, 31, 16, 8 mm.
doi:10.1371/journal.pone.0009854.t001
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were higher using fixed optimal thresholds than using automatic
thresholds (Table 2). Trabecular parameters (TbN, BV/TV &
TbSp) derived using optimal thresholds correlated among in vivo
and ex vivo mCT (Table 4), and among in vivo or ex vivo mCT
and histomorphometry (Table 2). Although we did not find good
correlations between TbTh values obtained by mCT and bone
histomorphometry, TbTh correlated moderately between in vivo
and ex vivo mCT at 16, 31, or 8-mm voxel sizes, and among ex vivo
mCT at the three voxel sizes (Table 4). Therefore, we used fixed
optimal thresholds at different voxel sizes to compare trabecular
parameters on mCT with those on bone histomorphometry.
2.4. BMD of Trabeculae of Metaphysis
In vivo and ex vivo mCT demonstrated decreases in the BMD of
the metaphyseal trabeculae in femora with tumors compared to
control femora at all voxel sizes (P,0.05, n=11, Figure 6A,
Table 3). The BMD of the trabeculae at the metaphyses was
highly correlated between in vivo mCT and ex vivo mCT at all
voxel sizes (Table 1).
2.5. Morphometric Trabecular Parameters
Trabeculae appeared better defined with decreasing voxel size
of mCT, and trabecular thinning, thickening, and loss could be
identified (Figures 1 and 3). With automatic or optimized
thresholds, correlations of trabecular parameters by mCT and
bone histomorphometry trended toward increasing as the voxel
size decreased from 91 mmt o8 mm (Table 2), but the
correlations were low (data not shown). Ten weeks after
inoculation, a significant difference in all trabecular parameters
except TbTh was seen between left and right femora on in vivo
mCT and ex vivo mCT at all voxel sizes using optimal thresholding,
concordant with histomorphometry. There were decreases in TbN
and BV/TV, and increase in TbSp in femora with tumors
compared to control femora by in vivo mCT or ex vivo mCT at all
voxel sizes (Figure 6B, C and D insets, Table 3) using optimal
thresholding, consistent with overall trabecular loss. This was not
seen with automatic thresholding for TbN and BV/TV by in vivo
mCT or ex vivo at 31 mm or with TbSp by in vivo or ex vivo mCT
at any voxel size; this result demonstrates the importance of using
fixed optimal thresholding instead of automatic thresholding.
Fixed optimal thresholding demonstrated that prostate cancer
involving bone altered trabecular morphology.
Discussion
Prostate cancer involving the skeleton results in a host bone
response that can be quantified by in vivo and ex vivo mCT in a
mouse model. Although there was heterogeneity in the trabeculae
affected by cancer (with thinning, thickening, and loss), overall
there was trabecular loss in femora with tumor as exemplified by
decreased TbN, BV/TV, and BMD, as well as increased TbSp; in
contrast, diaphyseal cortex thickened. In addition to the effect of
growth factors, data with the current mouse model suggest that a
likely mechanism for the findings is tumor-induced loss of
trabecular bone that causes both a trabecular bone reaction and
cortical thickening to stabilize the loss of mechanical strength of
the bone. This may be further tested in future studies. Findings
Figure 6. Assessment of trabecular morphologic parameters is threshold dependent; and, trabecular parameters are altered by
prostate cancer involving bone. Variations in correlation coefficient (r) for metaphyseal bone mineral density (BMD, A), trabecular number (TbN,
B) bone volume density (BV/TV, C), and trabecular separation (TbSp, D) by mCT at different thresholds and bone histomorphometry. Insets: using
optimal thresholds, in vivo mCT at 91-mm voxel size shows significant differences in metaphyseal BMD (BMD, A), TbN (TbN, B), BV/TV (BV/TV, C) and
TbSp (TbSp, D) between left and right femora 10 weeks after tumor inoculation.
doi:10.1371/journal.pone.0009854.g006
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trabecular bone since these may be discordant, especially in
cancer. This suggests that it will become important to evaluate
trabecular parameters as spatial resolution of clinical CT improves
to a degree that allows such assessment.
We compared the abilities of three imaging methods to evaluate
bone response to tumor: in vivo mCT, ex vivo specimen mCT and
ex vivo DXA. All three imaging methods were able to distinguish
BMD increases in the diaphyses, consisting primarily of cortical
bone, of the femora with tumors. Compared to mCT-derived
BMD, DXA-derived BMD had a lower coefficient of correlation
with bone histomorphometry. This is consistent with findings by
Barou et al. who also noted lower correlation between DXA and
bone histomorphometry in a rat model [23]. In addition, DXA
was unable to separate cortical bone from trabecular bone,
whereas mCT could. A limitation of ex vivo mCT at the 8-mm voxel
size was its small field of view that resulted in evaluation of only the
metaphysis. It also required a relatively longer computing time. Ex
vivo mCT at the 31 or 16-mm voxel size allowed imaging of the
entire femur. With increasing resolution, we noted a trend toward
higher correlation of trabecular parameters with histomorphom-
etry, but the trend was not statistically significant. Surprisingly,
even with relatively low spatial resolution, trabecular parameters
could be assessed by in vivo mCT, thus, enabling longitudinal
Table 2. Correlations between metaphyseal BMD and bone structural parameters derived by bone histomorphometry, in vivo
mCT, or ex vivo specimen mCT 10 weeks after tumor inoculation.
Technique and parameter Model Threshold (HU) r P
In vivo mCT, 91 mm vs Histomorphometry
TbN O
* 400 0.81 ,0.001
A
* 6336220 0.53 ,0.02
TbSp O 400 0.78 ,0.001
A6 3 3 6220 0.60 ,0.002
BV/TV O 400 0.73 ,0.001
A6 3 3 6220 0.58 ,0.003
BMD O 400 0.78 ,0.001
A6 3 3 6220 0.78 ,0.001
Ex vivo mCT, 31 mm vs Histomorphometry
Tb N O 2000 0.78 ,0.001
A 18306650 0.61 ,0.002
Tb Sp O 2000 0.73 ,0.001
A 18306650 0.57 ,0.001
BV/TV O 2000 0.79 ,0.001
A 18306650 0.58 ,0.001
BMD O 2000 0.75 ,0.001
A 18306650 0.75 ,0.001
Ex vivo mCT, 16 mm vs Histomorphometry
Tb N O 2000 0.88 ,0.02
A 24236770 0.73 ,0.3
Tb Sp O 2000 0.8 ,0.001
A 24236770 0.61 ,0.001
BV/TV O 2000 0.82 ,0.001
A 24236770 0.69 ,0.001
BMD O 2000 0.77 ,0.001
A 24236770 0.77 ,0.001
Ex vivo mCT, 8 mm vs Histomorphometry
TbN O 3000 0.90 ,0.001
A 18226920 0.71 ,0.001
TbSp O 3000 0.84 ,0.001
A 18226920 0.69 ,0.001
BV/TV O 3000 0.83 ,0.001
A 18226920 0.71 ,0.001
BMD O 3000 0.84 ,0.001
A 18226920 0.83 ,0.001
*O, optimal threshold; A, automatic threshold.
doi:10.1371/journal.pone.0009854.t002
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10 weeks after tumor inoculation.
Technique and parameter Model Threshold Mean Value
Femur w/o tumor Femur with tumor P
In vivo mCT, 91 mm
TbN (/mm) O
* 400 2.9 1.6 ,0.05
A
* 6336220 2.4 2.2 ,0.50
TbSp (mm) O 400 0.11 0.26 ,0.002
A6 3 3 6220 0.41 0.54 ,0.50
BV/TV (%) O 400 0.89 0.4 ,0.002
A6 3 3 6220 0.25 0.16 ,0.08
TbTh (mm) O 400 0.3 0.13 ,0.001
A6 3 3 6220 0.13 0.11 ,0.13
BMD (mg/cm
3) O 400 217 150 ,0.004
A6 3 3 6220 227 150 ,0.004
Ex vivo mCT, 31 mm
TbN (/mm) O 2000 2.88 1.2 ,0.005
A 18306650 2.95 2.24 ,0.12
TbSp (mm) O 2000 0.5 9.96 ,0.05
A 18306650 0.32 0.45 ,0.48
BV/TV (%) O 2000 0.11 0.05 ,0.02
A 18306650 0.12 0.11 ,0.78
TbTh (mm) O 2000 0.039 0.034 ,0.15
A 18306650 0.041 0.054 ,0.03
BMD (mg/cm
3) O 2000 451 342 ,0.02
A 18306650 463 342 ,0.02
Ex vivo mCT, 16 mm
TbN (/mm) O 2000 4.2 1.77 ,0.001
A 24236770 3.4 2.14 ,0.03
TbSp (mm) O 2000 0.29 1.08 ,0.02
A 24236770 0.3 0.54 ,0.20
BV/TV (%) O 2000 0.13 0.05 ,0.005
A 24236770 0.1 0.06 ,0.03
TbTh (mm) O 2000 0.032 0.035 ,0.56
A 24236770 0.03 0.034 ,0.20
BMD (mg/cm3) O 2000 475 344 ,0.006
A 24236770 482 353 ,0.006
Ex vivo mCT, 8 mm
TbN (/mm) O 3000 5.7 2.4 ,0.001
A 18226920 13 37 ,0.001
TbSp (mm) O 3000 0.25 2.17 ,0.05
A 18226920 0.1 0.05 ,0.06
BV/TV (%) O 3000 0.1 0.04 ,0.02
A 18226920 0.16 0.31 ,0.03
Tb Th (mm) O 3000 0.02 0.016 ,0.40
A 18226920 0.015 0.013 ,0.39
BMD (mg/cm
3) O 3000 500 333 ,0.006
A 18226920 486 339 ,0.006
Histomorphometry
TbN (/mm) 3.96 2.45 ,0.003
TbSp (mm) 0.22 0.29 ,0.05
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evaluate change in mineralized bone density and trabecular
architecture over time, which may be caused by disease or
therapy, for example, in animal models. In vivo mCT and ex vivo
mCT quantified the BMD of the cortex and trabeculae well. In
comparing different imaging modalities/machines for assessing
BMD, it is commonly necessary to add a correction factor [30].
BMD determined by ex vivo mCT was 2.2 times higher than the
BMD determined by in vivo mCT and because the correlation
between these modalities was high, a correction factor of 2.2 could
be applied when comparing in vivo mCT BMD with ex vivo mCT
BMD.
In vivo or ex vivo mCT trabecular morphometric parameters
(TbN, TbSp, and BV/TV) correlated well with bone histomor-
phometry. Most mCT studies of bones have used samples from rats
[21], [23], [31] or humans [32-34], who have larger bones and
trabeculae than mice. Owing to differences in size among species,
voxel size should be considered. Muller et al. [35] found high
correlations for BV/TV (r=0.91) and TbSp (r=0.91) of human
bone biopsy specimens by 14-mm3 DmCT and histomorphometry.
For BV/TV, TbN, and TbTh of human ilium, Uchiyama, et al.
[36] reported correlations of r=0.95, 0.75, 0.86, respectively,
comparing 2D mCT (spatial resolution, 26-mm) and bone
histomorphometry. For BV/TV, TbN, TbSp, and TbTh of
human vertebrae, Peyrin et al. noted high correlation (r.0.93)
between 6.6 mm Synchrotron CT and histomorphometry [33]. We
also found that TbTh derived from in vivo mCT moderately
correlated with ex vivo mCT at all voxel sizes; however, poor
correlation was observed between TbTh by bone histomorphom-
etry and by in vivo or ex vivo mCT. This may be due to several
factors including volume averaging of the small mouse trabeculae
[37], [38] and sampling error, since only three bone slices (right,
mid, and left sagittal planes/fermur) per femur were assessed by
bone histomorphometry and bone loss in the metaphysis was
expectedly inhomogeneous in the tumor model. Correlations of
TbTh were higher among mCT methods. Using a rat model of
disuse osteoporosis, Barou, et al. [23] found poor correlation for
TbTh by mCT versus bone histomorphometry and suggested that
3D- mCT may be more sensitive than histomorphometry in
detecting changes in BMD and trabeculae.
In contrast to assessment of BMD, where thresholding was not a
factor, the choice of thresholding significantly affected the
assessment of trabecular morphometric parameters. Automatic
thresholding and maximum gray-scale thresholding led to
variability in morphometric values between animals and the
femora with and without tumors. Further, neither correlated well
with trabecular parameters as assessed by histomorphometry. In
comparison, correlations of morphometric trabecular parameters
(TbN, BV/TV, and TbSp) by histomorphometry with mCT were
high using a fixed ‘‘optimal threshold’’. We found that mCT at
each voxel size had a separate ‘‘optimal’’ fixed threshold. To our
knowledge, these findings have not been reported previously.
Supporting our data, Ruegsegger et al. [32], [37] showed in a
human iliac crest biopsy specimen model that a 10% change in the
threshold resulted in a 5% change in BV/TV using 28 mm CT.
Bouxsein et al. [39] described trabecular and cortical bone
changes of inbred strains of mice using mCT with a threshold of
22% of maximal gray-scale value for vertebrae and tibia and 30%
for mid-femoral cortical bone. In the current setting, we found that
maximal gray scale values can vary and may not overlap with
‘‘optimal thresholds,’’ especially when tumor is present. Using
automatic thresholding, differences between morphologic trabec-
ular parameters were difficult to distinguish between femora with
and without tumor; whereas, such differences were clearly
Technique and parameter Model Threshold Mean Value
Femur w/o tumor Femur with tumor P
BV/TV (%) 10 6 ,0.006
TbTh (mm) 0.036 0.039 ,0.27
*O, optimal threshold; A, automated threshold.
doi:10.1371/journal.pone.0009854.t003
Table 3. Cont.
Table 4. Correlations between metaphyseal morphometric
parameters (TbN, TbSp, BV/TV, and TbTh) determined by in
vivo mCT vs ex vivo specimen mCT at optimal thresholds.
Parameter and mCT technique r P
TbN, 91 mmv s3 1mm 0.78 ,0.001
TbN, 91 mmv s1 6mm 0.81 ,0.001
TbN, 91 mmv s8mm 0.76 ,0.001
TbN, 31 mmv s1 6mm 0.88 ,0.001
TbN, 31 mmv s8mm 0.85 ,0.001
TbN, 16 mmv s8mm 0.89 ,0.001
TbSp, 91 mmv s3 1mm 0.77 ,0.001
TbSp, 91 mmv s1 6mm 0.77 ,0.001
TbSp, 91 mmv s8mm 0.88 ,0.001
TbSp, 31 mmv s1 6mm 0.81 ,0.001
TbSp, 31 mmv s8mm 0.84 ,0.001
TbSp, 16 mmv s8mm 0.74 ,0.001
BV/TV, 91 mmv s3 1mm 0.88 ,0.001
BV/TV, 91 mmv s1 6mm 0.86 ,0.001
BV/TV, 91 mmv s8mm 0.74 ,0.001
BV/TV, 31 mmv s1 6mm 0.87 ,0.001
BV/TV, 31 mmv s8mm 0.79 ,0.001
BV/TV,16 mmv s8mm 0.82 ,0.001
TbTh, 91 mmv s3 1mm 0.43 ,0.05
TbTh, 91 mmv s1 6mm 0.24 ,0.27
TbTh, 91 mmv s8mm 0.58 ,0.005
TbTh, 31 mmv s1 6mm 0.46 ,0.03
TbTh, 31 mmv s8mm 0.69 ,0.001
TbTh, 16 mmv s8mm 0.6 ,0.003
*In vivo mCT, 91 mm; Ex vivo mCT, 31, 16, 8 mm.
doi:10.1371/journal.pone.0009854.t004
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histomorphometry. Therefore, our data suggests that using fixed
optimal thresholds is important for obtaining robust trabecular
morphometric parameter values.
The results of this study using mCT to quantitatively
characterize the mineralized component of mouse femora may
be applicable to other studies of bones in small animals and
humans. For example, one may evaluate bone response to
strategies aimed at prevention or treatment of prostate bone
metastases, primary bone tumor, or metastases from other primary
tumors. The results also have the potential to be generalized to
other bone models, such as metabolic bone disease.
Clinical multi-slice CT scanners are approaching resolutions
fine enough for assessing trabeculae. Our data imply that each
voxel size used will require optimization of thresholding.
Automatic thresholding or maximum gray-scale thresholding will
need validation because they may be too variable to achieve
consistent results clinically. A fixed optimal threshold may be
superior for assessing morphometric parameters. Because 70% of
the effects of metabolic bone disease are first reflected in the
trabeculae and only 30% in the cortex [40] and because bone
metastases begin in the marrow, evaluation of the trabeculae may
detect metabolic bone disease and we suspect also metastatic
disease earlier than evaluation of the cortex. Since BMD was
independent of voxel size and thresholding in the current study
and given the sub-millimeter voxel size of new clinical scanners, it
is feasible that clinical multi-slice CT may soon be used to
determine BMD of the trabeculae to assess metabolic and
neoplastic disease in patients. This requires further study.
Morphometric parameters may also be added as clinical scanner
voxel size improves. Findings suggest that separately evaluating
cortex and trabeculae is important because the effects of pathology
on the mineralized components of these two types of bone may be
discordant.
In vivo mCT enables noninvasive, longitudinal assessment of
mineralized bone. Ex vivo specimen mCT enables nondestructive
assessment of mineralized bone enabling further study, for
example, by histology. With appropriate thresholding, in vivo
and ex vivo mCT can be used to quantify host response of both
cortical and trabecular mineralized bone to prostate cancer
involving the skeleton, and such a response may be different
between these two mineralized bone compartments.
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